GTBP — GT Biopharma Balance Sheet
0.000.00%
Last trade - 00:00- $7.02m
- $4.49m
Annual balance sheet for GT Biopharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 5.3 | 32 | 16.5 | 14 | 3.95 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 5.66 | 32.2 | 16.6 | 14.1 | 4.23 |
| Net Property, Plant And Equipment | 0 | — | 0.165 | 0.053 | 0 |
| Other Long Term Assets | |||||
| Total Assets | 5.66 | 32.2 | 16.7 | 14.1 | 4.23 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Current Portion of Long Term Debt / Capital Leases | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 35.1 | 10.3 | 4.94 | 6.63 | 5.9 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Minority Interest | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 34.9 | 10.3 | 5 | 6.63 | 5.9 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | -29.3 | 21.9 | 11.7 | 7.48 | -1.67 |
| Total Liabilities & Shareholders' Equity | 5.66 | 32.2 | 16.7 | 14.1 | 4.23 |
| Total Common Shares Outstanding | |||||
| Total Preferred Shares Outstanding |